{"contentid": 487944, "importid": NaN, "name": "Companies team up on mRNA vaccines for infectious diseases to protect against highly mutagenic viruses", "introduction": "ConserV Bioscience, a UK biotech focused on developing vaccines that protect against endemic and emergent infectious diseases, has entered into a collaboration with Belgian company eTheRNA immunotherapies.", "content": "<p>ConserV Bioscience, a UK biotech focused on developing vaccines that protect against endemic and emergent infectious diseases, has entered into a collaboration with Belgian company eTheRNA immunotherapies.</p>\n<p>The companies have agreed to collaborate on the development of vaccine candidates for infectious diseases.</p>\n<p><span class=\"pullQuote\">\"This follows the recent collaboration with the US government&rsquo;s Lawrence Livermore National Laboratory to develop a broad-spectrum coronavirus vaccine\"</span>It is hoped that by combining ConserV&rsquo;s and eTheRNA&rsquo;s technologies, the new vaccines will induce potent immune responses to protect against highly mutagenic viruses.</p>\n<p>This collaboration brings together ConserV&rsquo;s expertise in identifying broadly-protective antigens and eTheRNA&rsquo;s TriMix immunostimulatory mRNA technology and novel lipid nanoparticle encapsulation technologies.</p>\n<p>Initially, the collaboration will focus on development and evaluation of mRNA vaccine formulations against human immunodeficiency virus (HIV), with the objective of identifying a lead formulation to move forward to clinical development.</p>\n<p>The collaboration may also develop other mRNA vaccine formulations based upon ConserV&rsquo;s antigen portfolio.</p>\n<p>Kimbell Duncan, chief executive of ConserV Bioscience, said: &ldquo;Our mission is to develop safe and effective vaccines which offer broad protection against infections from viruses that mutate frequently.</p>\n<p>&ldquo;We are pleased to be working with eTheRNA to develop mRNA-based vaccine formulations of our antigen constructs, in combination with eTheRNA&rsquo;s TriMix and LNP technologies, in order to expand our development pipeline. This follows the recent collaboration with the US government&rsquo;s Lawrence Livermore National Laboratory to develop a broad-spectrum coronavirus vaccine.&rdquo;</p>", "date": "2021-03-04 12:48:00", "meta_title": NaN, "meta_keywords": NaN, "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-04 12:44:53", "updated": "2021-03-04 13:39:43", "access": NaN, "url": "https://www.thepharmaletter.com/article/companies-team-up-on-mrna-vaccines-for-infectious-diseases-to-protect-against-highly-mutagenic-viruses", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "conserv_bioscience_large.png", "image2id": "conserv_bioscience_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Deals, Research", "geography_tag": "Belgium, UK", "company_tag": "ConserV Bioscience, eTheRNA, eTheRNA immunotherapies", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-04 12:48:00"}